GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Anthropic IPO Marketing Expected to Start in Mid-October 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
OpenAI Nears Astra AI Model Launch With Safety Focus 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Xiaomi Shares Jump on Europe EV Expansion Plan 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Add as a preferred source on Google
RANCHO CORDOVA, Calif., Feb. 26, 2018 -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL) a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced the commercial launch of its AXP II system for the advanced isolation, collection and storage of hematopoietic stem cell concentrates from cord blood and peripheral blood.
“Since its introduction in 2006, our AXP system has been viewed as the gold standard in the volume reduction processing of cord blood, and we count many of the world’s leading public and private cord blood banks among our current long-time customers,” said Chris Xu, PhD, chief executive officer of Cesca Therapeutics. “Our first generation AXP system consistently achieves stem cell recovery rates in excess of 97%, the highest in the industry. With AXP II, we are introducing important enhancements to the AXP device, docking station, and proprietary XpressTRAK® software that together represent the biggest advancement in automated cord blood processing in many years. With the commercial launch of AXP II, we are continuing to fulfill our commitment to provide the highest quality, most innovative products to the cord blood bank market.”
AXP II is a complete, automated and functionally closed system that includes the AXP II device, docking station, processing set, and XpressTRAK software that maintains compliance with Current Good Manufacturing Practice (cGMP) and Current Good Tissue Practice (cGTP) regulations.
For more information, please visit: www.thermogenesis.com.
About Cesca Therapeutics Inc.
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress platform that addresses the critical unmet need for better cellular manufacturing and controls (CMC) for the emerging CAR-T immunotherapy market. Cesca is an affiliated company of China-based Boyalife Group.
Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
[email protected]
Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
[email protected]
